ONI Names Sharon Krumm, PhD, RN, Editor of Oncology Nursing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

MELVILLE, New York-The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.

MELVILLE, New York—The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.

Since 1996, she has been administrator and director of nursing at The Johns Hopkins Oncology Center, Baltimore. She is also assistant professor at The Johns Hopkins University Schools of Medicine and Nursing. Previously, she was director of nursing at the University of Missouri, Ellis Fischel Cancer Center. She joined Johns Hopkins in 1988 as director of nursing.

Dr. Krumm serves on the Board of Trustees of the American Cancer Society Mid-Atlantic Division. She has extensive research experience and is currently principal investigator for a study evaluating Johns Hopkins’ inpatient/outpatient care continuum program. She is the author, coauthor, or editor of 30 journal articles or abstracts and seven books.

Dr. Krumm brings to ONI a wealth of knowledge in the oncology nursing field and will be actively involved in selecting material specifically of interest to oncology nurses.

Recent Videos
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
2 experts are featured in this series.
2 experts are featured in this series.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Related Content